CRCHUM - Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada. Institut du cancer de Montréal, Montréal, Quebec, Canada.
CRCHUM - Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
Cancer Res. 2016 Sep 1;76(17):5080-91. doi: 10.1158/0008-5472.CAN-16-1071. Epub 2016 Jun 30.
The protein tyrosine phosphatase PTPRJ/DEP-1 has been implicated in negative growth regulation in endothelial cells, where its expression varies at transitions between proliferation and contact inhibition. However, in the same cells, DEP-1 has also been implicated in VEGF-dependent Src activation, permeability, and capillary formation, suggesting a positive role in regulating these functions. To resolve this dichotomy in vivo, we investigated postnatal angiogenesis and vascular permeability in a DEP-1-deficient mouse. In this study, we report that DEP-1 is required for Src activation and phosphorylation of its endothelial cell-specific substrate, VE-cadherin, after systemic injection of VEGF. Accordingly, VEGF-induced vascular leakage was abrogated in the DEP-1-deficient mice. Furthermore, capillary formation was impaired in murine aortic tissue rings or Matrigel plugs infused with VEGF. In the absence of DEP-1, angiogenesis triggered by ischemia or during tumor formation was defective, which in the latter case was associated with reduced tumor cell proliferation and increased apoptosis. Macrophage infiltration was also impaired, reflecting reduced vascular permeability in the tumors or a possible cell autonomous effect of DEP-1. Consequently, the formation of spontaneous and experimental lung metastases was strongly decreased in DEP-1-deficient mice. In clinical specimens of cancer, less vascularized tumors exhibited lower microvascular expression of DEP-1. Altogether, our results established DEP-1 as an essential driver of VEGF-dependent permeability, angiogenesis, and metastasis, suggesting a novel therapeutic route to cancer treatment. Cancer Res; 76(17); 5080-91. ©2016 AACR.
蛋白酪氨酸磷酸酶 PTPRJ/DEP-1 已被牵涉到内皮细胞中的负向生长调控,其表达在增殖和接触抑制之间的转变中变化。然而,在相同的细胞中,DEP-1 也被牵涉到 VEGF 依赖的Src 激活、通透性和毛细血管形成,表明其在调节这些功能中具有正向作用。为了在体内解决这种二分法,我们在 DEP-1 缺陷小鼠中研究了出生后血管生成和血管通透性。在这项研究中,我们报告 DEP-1 在系统注射 VEGF 后,Src 的激活和内皮细胞特异性底物 VE-cadherin 的磷酸化是必需的。因此,DEP-1 缺陷小鼠中 VEGF 诱导的血管渗漏被阻断。此外,在 VEGF 输注的小鼠主动脉组织环或 Matrigel 塞中,毛细血管形成受损。在缺乏 DEP-1 的情况下,由缺血或肿瘤形成引发的血管生成受损,在后一种情况下,与肿瘤细胞增殖减少和凋亡增加有关。巨噬细胞浸润也受损,反映了肿瘤中的血管通透性降低或 DEP-1 的可能细胞自主效应。因此,DEP-1 缺陷小鼠自发和实验性肺转移的形成强烈减少。在癌症的临床标本中,血管化程度较低的肿瘤表现出较低的微血管 DEP-1 表达。总之,我们的结果确立了 DEP-1 作为 VEGF 依赖的通透性、血管生成和转移的必需驱动因素,提示了癌症治疗的新治疗途径。癌症研究; 76(17); 5080-91. ©2016 AACR.